GlassScriptPhysician profile
Anand M Gupta
NPI 1841299138
$3,833.72
in general payments reported to CMS, 2019-2025
23 companies · $858 in 2025
The $858 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $41.56 · 2021: $581 · 2022: $713 · 2023: $457 · 2024: $772 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617 · Travel and Lodging: $470.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.93 |
| Travel and Lodging | $469.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Synthes Gmbh | $469.64 | 2025 | |
| Phathom Pharmaceuticals, INC. | $402.97 | 2023-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $365.50 | 2021-2024 | |
| Boston Scientific Corporation | $357.26 | 2019-2021 | |
| Amgen INC. | $286.67 | 2025 | Tepezza |
| Genzyme Corporation | $235.90 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.81 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $204.50 | 2022-2024 | Ibsrela |
| Abbvie INC. | $183.50 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $160.78 | 2019-2022 | |
| Atricure, INC. | $156.25 | 2022 | |
| Braintree Laboratories, INC. | $125.31 | 2022-2025 | Suflave |
| Redhill Biopharma INC. | $125.30 | 2020-2022 | |
| Esperion Therapeutics, INC. | $122.15 | 2022 | |
| Intercept Pharmaceuticals, INC. | $93.39 | 2019-2023 | Ocaliva |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $82.20 | 2024 | Azure Xt Dr Mri Surescan |
| Takeda Pharmaceuticals U.S.A., INC. | $66.85 | 2019 | |
| Celgene Corporation | $45.11 | 2022 | |
| Janssen Biotech, INC. | $33.08 | 2019-2023 | Stelara |
| Ferring Pharmaceuticals INC. | $32.09 | 2019 | |
| Albireo Pharma, INC. | $22.45 | 2024 | Iqirvo |
| Acacia Pharma INC | $18.34 | 2021 | |
| Echosens North America, INC. | $12.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Gupta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.